Compounding Limits and Where Compounding Becomes Manufacturing
A pharmacy that compounds on a patient-specific prescription sits inside a statutory exemption. Compounding ahead of demand, in quantity, or for office stock moves the activity toward a different regime with registration and manufacturing obligations attached.
The rule in short
Compounding by a licensed pharmacist or physician is exempt from new drug approval, adequate directions labeling and good manufacturing practice only if statutory conditions hold, including a prescription for an identified patient and limits on copying commercially available drugs. An outsourcing facility may compound without patient-specific prescriptions but must register, follow manufacturing practice rules and report adverse events.
Compounding sits in a statutory exemption, and an exemption has edges. A pharmacy preparing a preparation for one named patient on one prescription is plainly inside it. A pharmacy producing batches for stock, for other practitioners, or for sale, is somewhere else, and the question is not whether the work is skilled but which regulatory regime applies to it.
The exemption and what it buys
Drugs compounded under the traditional provision are exempt from three heavy obligations: new drug approval, the requirement that labeling bear adequate directions for use, and compliance with current good manufacturing practice.
Those exemptions are conditional. The compounding must be by a licensed pharmacist in a state licensed pharmacy or federal facility, or by a licensed physician, for an identified individual patient, based on the receipt of a valid prescription order or a notation approved by the prescriber that a compounded product is necessary for that patient.
Limited advance preparation is contemplated. A pharmacist may compound in limited quantities before receiving a valid prescription where there is a history of receiving such prescriptions generated within an established relationship between the pharmacist, the patient and the prescriber. The quantity must bear a relationship to that history rather than to expected demand generally.
The conditions that decide the question
Beyond the patient-specific requirement, the exemption depends on what is being compounded and from what.
Bulk drug substances must satisfy one of three routes: they comply with the standards of an applicable monograph and the monograph requirements of the National Formulary or the United States Pharmacopeia; or they are components of a drug approved by the agency; or they appear on a list of substances established by rule. In every case they must be manufactured by an establishment registered with the agency and be accompanied by a valid certificate of analysis. Ingredients other than bulk drug substances must comply with the applicable monograph standards.
Two prohibitions sit on top. The pharmacist may not compound a drug that appears on a published list of products withdrawn or removed from the market because they were found unsafe or ineffective. And the pharmacist may not compound regularly or in inordinate amounts any drug product that is essentially a copy of a commercially available drug product.
A further condition looks outward rather than inward. The exemption is unavailable where the drug is compounded in a state that has not entered a memorandum of understanding with the agency addressing the distribution of inordinate amounts of compounded product out of state, unless the pharmacy limits interstate distribution to a stated proportion of the total prescription orders it dispenses or distributes. A pharmacy shipping across state lines therefore has to know both what it ships and what its state has agreed.
| Question | Traditional compounding | Outsourcing facility |
|---|---|---|
| Patient-specific prescription | Required, with limited anticipatory preparation | Not required |
| Registration with the agency | Not required; state pharmacy licensure applies | Required, with periodic reporting of what is compounded |
| Good manufacturing practice | Exempt | Must comply |
| Labeling | Exempt from adequate directions for use | Prescribed content, including a statement identifying it as compounded |
| Adverse event reporting | Governed by state law | Required by statute |
| Inspection | Primarily by the state board | Risk-based federal inspection |
The office stock problem
The most common way a pharmacy drifts out of the exemption is by supplying practitioners with product to keep on hand. There is no patient at the point of preparation, so the patient-specific condition cannot be met, and the activity looks like distribution rather than dispensing.
Federal drug law answers this by pointing at the outsourcing facility category, which exists precisely to allow compounding without patient-specific prescriptions under a heavier compliance burden. State pharmacy law answers it separately, and many states permit limited office use supply by a compounding pharmacy under conditions of their own, with quantity limits, labeling requirements and record obligations attached.
Where controlled substances are involved a third rule appears. A dispenser may distribute to another practitioner only within a stated proportion of the total dosage units the dispenser distributes and dispenses in a calendar year, and exceeding that proportion requires a distributor registration. That limit is easy to breach without noticing, because the numerator grows quietly while the denominator sits in a different system. The registration structure that governs it is described under registration by activity and location.
The statute prohibits compounding a drug essentially a copy of a commercially available product regularly or in inordinate amounts. A one-off preparation for a patient who cannot tolerate an excipient is not the target. A pharmacy that prepares the same non-patient-specific formulation week after week, at volumes comparable to the approved product, has moved into the conduct the phrase describes, whatever the individual prescriptions say.
What the outsourcing facility route requires
An outsourcing facility is a facility that compounds sterile drugs, has elected to register as an outsourcing facility, and complies with the conditions attached. It may compound without receiving patient-specific prescriptions, which is the point of the category.
In exchange it registers with the agency, is subject to inspection on a risk-based schedule, must comply with current good manufacturing practice, must report the drugs it compounds during specified periods, and must submit adverse event reports. Its products must carry defined labeling, including a statement that the drug is a compounded drug and information on the facility and the ingredients.
An outsourcing facility need not be a licensed pharmacy, and where it is not, the compounding must be under the direct supervision of a licensed pharmacist. State licensure obligations continue to apply in the states where it ships.
Records, inspection and the two authorities
A compounding pharmacy is answerable to at least two authorities with different priorities. The state board of pharmacy inspects for compliance with pharmacy practice standards, sterile compounding requirements and record obligations. Federal drug law reaches the pharmacy through the conditions on the exemption, and federal controlled substance law reaches it through registration.
Those regimes ask different questions of the same records. The board wants to see formulation records, beyond-use dating and environmental monitoring. The controlled substance rules want receipts and dispositions that reconcile, which for a compounder means accounting for bulk substance consumed as well as finished units dispensed. Bulk substance that cannot be reconciled to finished preparations is an unexplained variance of exactly the kind covered by the theft and significant loss reporting duty.
The practical consequence is that a compounding operation needs a reconciliation that spans both systems, tying the quantity of controlled bulk substance received to the quantity incorporated into preparations, dispensed, wasted and destroyed. That reconciliation is the same exercise described under the records that must balance, made harder by the fact that the unit of measurement changes partway through the process.
Points to carry away
- The traditional compounding exemption requires a prescription for an identified individual patient, with limited advance preparation.
- Compounding drugs that are essentially copies of a commercially available drug falls outside the exemption.
- Bulk substances must meet monograph, approval or list conditions and come from a registered establishment with a certificate of analysis.
- An outsourcing facility may compound without patient-specific prescriptions but must register and follow good manufacturing practice.
- State pharmacy law governs office stock and non-patient-specific supply, and is frequently stricter than the federal position.
Questions readers ask
Can a pharmacy compound in advance of receiving prescriptions?
Within limits. The statute contemplates compounding in limited quantities before the receipt of a valid prescription, where the pharmacist has a history of receiving such prescriptions generated solely within an established relationship between the pharmacist, the patient and the prescriber. The quantity must be proportional to that history. Preparing a batch and then finding patients for it inverts the sequence the exemption depends on, and a pharmacy relying on anticipatory compounding should be able to produce the prescription history that justifies the quantity it made.
What makes a compounded drug essentially a copy?
The statutory phrase is a drug product that is essentially a copy of a commercially available drug product, and the analysis turns on whether the compounded product differs from the approved one in a way that makes a clinical difference for the patient. A change of flavoring, or removal of an inactive ingredient the patient tolerates, will generally not be enough. A documented determination by the prescriber that the change is significant for that patient is the usual basis for a compounded version, and the determination belongs in the record rather than in the pharmacy's assumption.
Does compounding a controlled substance change the analysis?
It adds a second regime rather than changing the first. The compounding exemptions are drug law, and they say nothing about registration, ordering, recordkeeping or security. A pharmacy compounding a Schedule II preparation still orders the bulk substance on the closed ordering system, still counts it exactly at inventory, and still records every disposition. Where compounding is done for another practitioner rather than for a patient, the distribution rules that limit a dispenser's ability to supply another practitioner apply on top of the compounding analysis.
Sources
- 21 U.S.C. § 353a — Pharmacy compoundingSets the conditions for the traditional compounding exemption, including the copy restriction.
- 21 U.S.C. § 353b — Outsourcing facilitiesCreates the outsourcing facility category and its registration and reporting duties.
- FDA — Human Drug Compounding Laws and PoliciesThe agency's collected statutory and policy materials on compounding.
- FDA — Registered Outsourcing FacilitiesThe published list of facilities that have registered under the outsourcing provision.
- FDA — Compounding and the FDA: Questions and AnswersExplains the practical distinctions between the two compounding regimes.
- 21 CFR § 1307.11 — Distribution by dispenser to another practitionerLimits the quantity a dispenser may supply to another practitioner without a distributor registration.
- 21 CFR § 1301.13 — Application and independent activitiesIdentifies when an activity requires a separate registration rather than coincident authority.
Metro Law Advisors is a publication, not a law firm. This article states general rules and cites its sources; it is not advice about any particular case, and the law differs by state and changes over time.
More in Pharmacy & Controlled Substances
Registering to Handle Controlled Substances
Federal law requires a separate registration for each principal place of business where controlled substances are manufactured, distributed or dispensed, and a separate registration for each independent group of activities. A practitioner registration depends on state authority to dispense: when the state license ends, the federal authority it rests on ends with it. Registrations expire on assigned cycles and must be modified when the address or the schedules handled change.
The Drug Schedules and What Each One Restricts
Congress set five schedules and gave the Attorney General authority to add, remove or move substances after a scientific and medical evaluation. Each placement rests on findings about abuse potential, accepted medical use and the dependence a substance produces. The schedule then determines the ordering, prescribing, refill, storage and recordkeeping rules that apply, and a change in schedule changes all of them at once.
Refills, Transfers and Partial Fills by Schedule
Schedule II prescriptions may not be refilled and their partial fills run on tight deadlines measured from the prescription or the first fill. Schedules III and IV permit up to five refills within six months of issue, and refill information may be transferred between pharmacies once unless they share a real-time database. Every partial fill and refill generates a record entry, and the total dispensed can never exceed the quantity prescribed.